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Purpose: To compare the kinetics and speed of kill of Streptococcus pneumoniae and   
Haemophilus influenzae on exposure to three topical ophthalmic antibiotic solutions. 
Materials and methods: Bacterial conjunctivitis isolates of S. pneumoniae and H. influenzae 
were exposed to 1:1000 dilutions of moxifloxacin 0.5%, tobramycin 0.3%, gentamicin 0.3%, and 
water (control). At 15, 30, 60, 120, and 180 minutes after exposure, aliquots were collected, cells 
were cultured, and viable cell counts were determined using standard microbiological methods.
Results: Moxifloxacin achieved 99.9% kill (3-log reduction) at approximately 2 hours for 
S. pneumoniae and at 15 minutes for H. influenzae. Tobramycin and gentamicin did not achieve 
3-log reduction of S. pneumoniae during the 180-minute study period. An increase in bacterial 
growth was noted for these isolates. Gentamicin took more than 120 minutes to achieve the 3-log 
reduction of H. influenzae and tobramycin did not reach the 3-log reduction of this pathogen 
during the 180-minute study period.
Conclusion: Moxifloxacin killed S. pneumoniae and H. influenzae in vitro faster than tobramycin 
and gentamicin, suggesting its potential clinical benefit as a first-line treatment for bacterial 
conjunctivitis to minimize patient symptoms and to limit the contagiousness of the disease.
Keywords: kinetics of kill, bacterial conjunctivitis, in vitro, Streptococcus pneumoniae, 
Haemophilus influenzae, fluoroquinolones, aminoglycosides
Introduction
Conjunctivitis is a common disease, with considerable social and economic 
consequences due to disruption of usual patient and/or caregiver activities, such as lost 
days of school and/or work. Conjunctivitis can be caused by many ocular pathogens, 
but is mainly bacterial or viral in origin, with approximately 78% to 80% of cases 
being bacterial in origin.1 Bacterial conjunctivitis is particularly common in children, 
with Streptococcus pneumoniae and Haemophilus influenzae being the most common 
causative organisms.2 The disease is characterized by mucopurulent discharge, con-
junctival injection, and morning matting of the lids.
The optimal treatment of bacterial conjunctivitis has been under debate for years. 
Opinions range from no treatment at all3 to treatment with new-generation fluoroquino-
lones.4 Although bacterial conjunctivitis is a self-limited disease lasting 7 to 14 days,2 
initial therapy that offers a quick eradication of the causative pathogen is preferred.5 
This rapid eradication minimizes contagiousness and allows for quick return to normal 
daily routines.6 In addition to bactericidal activity, an ophthalmic antibiotic should be 
safe, cost-effective, and have a favorable dosing regimen.Clinical Ophthalmology 2010:4 42
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Aminoglycosides are a group of antibiotics derived from 
various species of Streptomyces that interfere with the func-
tion of bacterial ribosomes. From the early to late 1980s, prior 
to the use of ophthalmic fluoroquinolones, aminoglycosides 
were used frequently as a treatment for bacterial conjunctivitis. 
Included in this group of ocular antibiotics are tobramycin 
ophthalmic solution 0.3% (Tobrex®; Alcon Laboratories, Inc., 
Fort Worth, TX, USA) and gentamicin ophthalmic solution 
0.3% (Genoptic®; Allergan, Inc., Irvine, CA, USA). The 
decreasing use of aminoglycosides is a result of the increas-
ing resistance of Gram-positive organisms to this class of 
antibiotics and the increasing incidence of adverse ocular 
reactions.7–9 Since the 1990s, fluoroquinolones have gained 
widespread acceptance in the treatment of bacterial conjunc-
tivitis because of the speed with which they eradicate bacteria. 
Fourth-generation fluoroquinolones provide the best coverage 
against Gram-positive organisms, including resistant strains, 
while maintaining coverage against Gram-negative organisms 
comparable to the earlier fluoroquinolones.10,11
Despite the advantages of topical fluoroquinolones, clini-
cians have had some reservations regarding their use. Some 
have been concerned with speculative side effects, which may 
be attributed to side effects based on product labeling for sys-
temic use. Some believe the use of topical fourth-generation 
fluoroquinolone antibiotics would lead to erosion of their 
clinical effectiveness to a greater degree than if the newer 
antibiotics were held in reserve and used only for patients 
who did not respond to initial therapy.4 Results from in vitro 
studies indicate that resistance to fourth-generation fluoro-
quinolones develops via multiple-step mutations.12 Therefore, 
fourth-generation fluoroquinolones maintain their clinical 
effectiveness because the probabilities of development of 
resistant strains in this class are much reduced. Additionally, 
clinicians may be less likely to prescribe newer antibiotics 
because of the perceived increase in cost,6 despite the more 
rapid kill, which can minimize the duration of symptoms and 
decrease contagion.
Moxifloxacin ophthalmic solution 0.5% (Vigamox®; 
Alcon Laboratories, Inc.) is a fourth-generation, 8-methoxy 
fluoroquinolone with a diazabicyclononyl ring at C7 position. 
The antibacterial action of moxifloxacin results from inhibi-
tion of the DNA gyrase and topoisomerase IV,13,14 whereas 
earlier-generation fluoroquinolones inhibited either DNA 
gyrase or topoisomerase IV. Moreover, the mechanism of 
action of the fourth-generation fluoroquinolones is different 
from that of macrolides, aminoglycosides, or tetracyclines, 
allowing moxifloxacin to be active against organisms that 
are resistant to these antibiotics.
The purpose of this study was to compare the time 
required in vitro for tobramycin and gentamicin (aminoglyco-
sides) and moxifloxacin (fourth-generation fluoroquinolone) 
to kill S. pneumoniae and H. influenzae, the most common 
causative organisms of bacterial conjunctivitis in children.
Materials and methods
Bacterial isolates of S. pneumoniae and H. influenzae were 
isolated from patients who had bacterial conjunctivitis. Mini-
mum inhibitory concentrations (MIC) of these two isolates 
for selected antibiotics were determined by broth micro 
dilution methods recommended by the National Committee 
for Clinical Laboratory Standards (NCCLS).
Kinetics of kill testing was used to compare the rates of 
kill of S. pneumoniae and H. influenzae by three ophthalmic 
products developed to topically treat bacterial conjunctivitis: 
moxifloxacin ophthalmic solution 0.5%, tobramycin ophthal-
mic solution 0.3%, and gentamicin ophthalmic solution 0.3%. 
Each product was tested at a 1:1000 dilution to approximate 
the concentrations remaining in the tear film 30 to 60 minutes 
after antibiotic instillation in the eye.4
S. pneumoniae growing logarithmically at 35 °C in cation-
adjusted Mueller-Hinton broth and H. influenzae growing log-
arithmically in Haemophilus Test Media broth were exposed to 
the diluted ophthalmic antibiotic products. At 15, 30, 60 min-
utes after exposure, aliquots of treated cells were withdrawn 
and serially diluted in cold phosphate-buffered saline with 
peptone. Aliquots containing S. pneumoniae (0.1 mL each) 
were spread onto trypticase soy agar plates supplemented 
with 5% sheep blood to determine the number of surviving 
colony-forming units per mL (CFU/mL). Likewise, 0.1 mL 
aliquots containing H. influenzae were spread onto chocolate 
agar plates. Plates were incubated at 35 °C for 24 hours and 
viable cell count was determined using standard methods.
Results
Kinetics of kill studies of moxifloxacin, tobramycin, and gen-
tamicin were conducted with S. pneumoniae (MCC 40211) 
and H. influenzae (MCC 95018). The MIC susceptibility 
profiles of these isolates to selected antibiotics are presented 
in Table 1, which is similar to profiles previously reported in 
the literature.4,6,15 The kinetics of kill data for the two isolates 
are presented in Figures 1 and 3 as percent survivors from 
initial CFU/mL.
Streptococcus pneumoniae
Use of 1:1000 dilution of moxifloxacin 0.5% (5 µg/mL) for 
S. pneumoniae resulted in a 99% reduction in the percentage Clinical Ophthalmology 2010:4 43
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of surviving CFU within 60 minutes of exposure and 99.9% 
reduction (3-log reduction) in the percentage of surviving CFU 
within 120 minutes of exposure. 1:1000 dilutions of tobramy-
cin 0.3% (3 µg/mL) and gentamicin 0.3% (3 µg/mL) showed 
an increase in bacterial growth over the 180-minute study 
period (Figure 1). Plate photographs showed that moxifloxacin 
achieved almost complete eradication of bacterial growth 
60 minutes after exposure, whereas tobramycin and genta-
micin showed an increased bacterial growth at 60 minutes 
when compared with baseline (Time 0) (Figure 2).
Haemophilus influenzae
Use of 1:1000 dilution of moxifloxacin 0.5% (5 µg/mL) for 
H. influenzae resulted in a greater than 99.9% reduction in 
the percentage of surviving CFU within 15 minutes of expo-
sure (Figure 3). 1:1000 dilutions of both tobramycin 0.3% 
(3 µg/mL) and gentamicin 0.3% (3 µg/mL) showed an increase 
in bacterial growth during the first 60 minutes of the study 
period. Gentamicin achieved a 3-log reduction of viable cell 
counts within 180 minutes of exposure, whereas tobramycin 
did not achieve the 3-log reduction during the 180-minute study 
period. Plate photographs showed that moxifloxacin achieved 
almost complete eradication of bacterial growth within 15 
minutes after exposure, whereas tobramycin and gentamicin 
Table 1 Minimum inhibitory concentration (µg/mL) of Streptococcus 
pneumoniae and Haemophilus influenzae isolates to selected 
antibiotics
Antibiotic  S. pneumoniae  
(MCC 40211)
H. influenzae  
(MCC 95018)
Moxifloxacin 0.125 0.015
Tobramycin 32 2
gentamicin 16 2
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Figure 1 Percent survivors of Streptococcus pneumoniae (MCC 40211) as a function 
of time.
showed an increased bacterial growth at 60 minutes when 
compared with baseline (Time 0) (Figure 4).
Discussion
The most appropriate antibiotic therapy for patients with 
contagious bacterial conjunctivitis should eliminate infec-
tion quickly to minimize both the signs and symptoms and 
the spread of the disease. The antibiotic also should be 
safe, well-tolerated, have a convenient dosing regimen to 
encourage adherence, and be cost-effective.16
The economic burden of bacterial conjunctivitis is substan-
tial and involves both direct and indirect costs. The direct costs 
of treating patients with bacterial conjunctivitis in the United 
States was estimated at approximately $765 million in 2005.17 
Currently, there is no consensus among state health officials 
regarding students’ absence(s) due to bacterial conjunctivitis. 
The issue of whether or not to require a child’s absence from 
school if the student is found to have bacterial conjunctivitis 
has to do with more than just the likelihood that the child will 
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Figure 2 Photographs of Streptococcus pneumoniae (MCC 40211) grown on blood 
agar plates after exposure to 1:1000 dilutions of moxifloxacin (5 μg/mL), tobramycin 
(3 μg/mL), gentamicin (3 μg/mL), and water control.Clinical Ophthalmology 2010:4 44
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State and/or Federal funding per student per missed school 
day (excused or unexcused).18,19 The 2009 United States 
Department of Labor’s Wage and Hour Division (WHD) 
federal minimum wage laws indicate that a minimum-wage 
earning parent or caregiver who loses one working day to care 
for a child with bacterial conjunctivitis loses between $41.20 
and $68.4 in wages, depending on the minimum wage set by 
the state.20 Therefore, the cost-effectiveness of an antibiotic, 
not simply the unit price, is an important measure that allows 
clinicians to choose the ideal antibiotics.5
This current study investigated the kinetics of kill of mox-
ifloxacin 0.5%, a commonly prescribed fourth-generation 
fluoroquinolone antibiotic, and two aminoglycoside anti-
biotics (tobramycin and gentamicin) on S. pneumoniae and 
H. influenzae, the two most commonly isolated organisms 
in bacterial conjunctivitis in children.2 The antibiotics 
were diluted 1:1000 to represent the concentration of the 
antibiotic in the eye 30 to 60 minutes after instillation.4 
Moxifloxacin demonstrated a more rapid bacterial kill than 
either one of the aminoglycosides, achieving 99.9% kill 
(bactericidal effect) of S. pneumoniae within 120 minutes of 
exposure and 99.9% kill of H. influenzae within 15 minutes 
of exposure. Aminoglycosides did not kill S. pneumoniae 
during the 180-minute study period, and their speed of 
bacterial kill of H. influenzae was much slower than that 
of moxifloxacin. Similar kinetics of kill studies conducted 
separately against H. influenzae with moxifloxacin ophthal-
mic solution 0.5% and fusithalmic acid 1.0% demonstrated 
similar results (data not shown). Moxifloxacin eradicated 
H. influenzae within 15 minutes while fusithalmic acid was 
unable to kill the bacteria during the 60-minute study period. 
Collectively, the findings from these in vitro studies suggest 
that moxifloxacin might eradicate rapidly S. pneumoniae 
and H. influenzae in patients with bacterial conjunctivitis, 
possibly translating into faster symptom resolution5,21 and 
a reduced chance of disease transmission. This may lead to 
a decrease in the number of days needed to achieve resolu-
tion of symptoms and the economic benefits of a reduction 
in the rate of school absenteeism by affected children and in 
the loss of work days by parents and/or caregivers.
There are some limitations to in vitro kinetics of kill studies. 
First, these studies report results based on a constant concentra-
tion of active product rather than the changing concentrations 
that are expected in the eye after instillation of the antibiotic. 
Second, kinetics of kill studies are conducted after a single 
exposure to antibiotics; therefore, the application of this model 
for bacteria exposed to multiple daily doses of antibiotic is 
unknown. For these reasons, results of in vitro kinetics of kill 
Figure 4  Photographs of Haemophilus influenzae (MCC 95018) grown on chocolate 
agar plates after exposure to 1:1000 dilutions of moxifloxacin (5 μg/mL), tobramycin 
(3 μg/mL), gentamicin (3 μg/mL), and water control.
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infect others. Students’ absenteeism affects their academic 
performance, the schools’ State and Federal funding, and 
employers’ productivity due to lost work time by parents or 
caregivers.5 It is estimated, depending on the state and the 
school district, that schools lose approximately $32 to $42 of 
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Figure 3 Percent survivors of Haemophilus influenzae (MCC 95018) as a function of time.Clinical Ophthalmology 2010:4
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studies should be confirmed in clinical studies, although few 
comparative clinical studies are available. Granet et al5 demon-
strated that moxifloxacin 0.5% dosed 3 times daily cured bacte-
rial conjunctivitis faster and more effectively than polymyxin 
B sulfate/trimethoprim dosed 4 times daily, with H. influenzae 
being the most commonly isolated organism in that study.
Conclusion
Kinetics of kill studies with moxifloxacin ophthalmic solution 
0.5% support a greater speed of kill against S. pneumoniae 
and H. influenzae than with the aminoglycosides, tobramy-
cin ophthalmic solution 0.3% and gentamicin ophthalmic 
solution 0.3%. Rapid bacterial eradication of pathogenic 
bacteria is a favorable characteristic of an antibiotic because 
it minimizes the spread of the disease and provides quicker 
clinical resolution, of which have tremendous socioeconomic 
impact on children and their families.
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